Skip to main content
. 2020 Jul 7;11:1005. doi: 10.3389/fphar.2020.01005

Figure 2.

Figure 2

Mouse locomotor activity (LMA) following administration of PF-6142. (A) Treatment with PF-6142 increases the number of beam breaks and pretreatment with the D1 antagonist, SCH-23390, effectively and dose dependently blocks the hyperactivity induced by PF-6142. (B) Daily administration of D1 agonists. (C) The hyperactive response is greatly diminished in the D1 KO mice compared to WT mice. Data are shown as the mean beam breaks + SEM. N = 8. One-way ANOVA with Dunnett’s post-test adjusted *p < 0.05, **p < 0.01 vehicle + PF-6142 (10 mg/kg) (A). Two-way ANOVA with Dunnett’s (B) or Tukey’s (C) post-test adjusted *p < 0.05, **p < 0.01 vs vehicle (B) or vehicle + vehicle (C).